Concepedia

Publication | Closed Access

Fenoldopam Mesylate for the Prevention of Contrast-Induced Nephropathy

DOI

407

Citations

38

References

2003

Year

Gregg W. Stone, Peter A. McCullough, James A. Tumlin, Norman E. Lepor, Hooman Madyoon, Patrick Murray, Andrew Wang, A. Alan Chu, Gary L. Schaer, Melissa Stevens,
JAMA

Abstract

The selective dopamine-1 agonist fenoldopam mesylate does not prevent further renal function deterioration after contrast administration in patients with chronic renal insufficiency.

References

YearCitations

Page 1